Hospital
Fort Payne Hospital Corporation
Fort Payne Hospital Corporation was paid $2.60M by Medicaid between Jan 2018 and Sep 2024, across 77 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoFORT PAYNE HOSPITAL CORPORATION
FORT PAYNE, AL 35968
FORT PAYNE, AL 35968
33aNPI1710901178assigned 07/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.60M
24GClaims109,474
24DCodes billed77
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#29 of 77
Median peer was paid$1.13M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,762 | $417K | |
| 2019 | 17,958 | $353K | |
| 2020 | 12,222 | $236K | |
| 2021 | 13,882 | $328K | |
| 2022 | 14,251 | $349K | |
| 2023 | 21,458 | $605K | |
| 2024incomplete | 8,941 | $308K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 13,076 | 11,283 | $755K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 15,714 | 14,027 | $569K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 1,774 | 1,545 | $335K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 8.1% | 2,440 | 2,123 | $209K |
| 80053 | Comprehensive metabolic panel | 4.8% | 13,967 | 11,966 | $125K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 15,520 | 13,281 | $113K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 1,118 | 775 | $43K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 1,083 | 1,014 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 660 | 568 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 4,624 | 3,988 | $37K |
| 31020 | 1.3% | 219 | 106 | $35K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 930 | 717 | $34K |
65 more codes
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.2% | 214 | $32K |
| 87430 | <1% | 1,594 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 742 | $25K |
| 81001 | <1% | 7,361 | $24K | |
| 87400 | <1% | 2,810 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,048 | $18K |
| 84484 | <1% | 2,034 | $12K | |
| 42830 | <1% | 31 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,105 | $8K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 321 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 147 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 528 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 847 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 44 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 134 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $5K |
| 81025 | <1% | 1,653 | $5K | |
| 31256 | <1% | 23 | $5K | |
| 83690 | <1% | 730 | $4K | |
| 59025 | Fetal non-stress test | <1% | 1,004 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 141 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 42 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 128 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $2K |
| 82607 | <1% | 84 | $1K | |
| 84480 | <1% | 84 | $1K | |
| 87807 | <1% | 99 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 153 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 150 | $1K |
| 81003 | <1% | 448 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 767 | $934.87 |
| 83874 | <1% | 138 | $661.50 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16 | $390.00 |
| 87077 | <1% | 54 | $346.74 | |
| 84436 | <1% | 84 | $317.58 | |
| 85027 | <1% | 144 | $311.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 254 | $299.20 |
| 80061 | Lipid panel | <1% | 38 | $296.65 |
| 87186 | <1% | 40 | $283.04 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 38 | $254.52 |
| 86803 | <1% | 13 | $207.24 | |
| 82150 | <1% | 27 | $165.57 | |
| 82553 | <1% | 17 | $136.08 | |
| 85379 | <1% | 12 | $101.07 | |
| 82550 | <1% | 17 | $76.80 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,237 | $68.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 28 | $53.20 |
| 86140 | <1% | 32 | $47.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 98 | $25.96 |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,577 | $9.44 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 484 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 632 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 28 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 96 | $0.00 |
| 94761 | 0% | 221 | $0.00 | |
| 87081 | 0% | 30 | $0.00 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 96 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 15 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 20 | $0.00 |
| 85018 | 0% | 90 | $0.00 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 16 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 31 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 84 | $0.00 |
| 85014 | 0% | 90 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OPERATIONS/AO)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.